查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972119

子宫内膜异位症治疗市场：依药物类别、给药途径、作用机制、产品类型、通路和最终用户划分－2026-2032年全球预测

Endometriosis Drugs Market by Drug Class, Route Of Administration, Mechanism Of Action, Product Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，子宫内膜异位症治疗市场价值将达到 28.9 亿美元，到 2026 年将成长至 31.1 亿美元，到 2032 年将达到 48 亿美元，复合年增长率为 7.49%。

主要市场统计数据
基准年 2025 28.9亿美元
预计年份：2026年 31.1亿美元
预测年份 2032 48亿美元
复合年增长率 (%) 7.49%

本书全面概述了影响子宫内膜异位症治疗和策略决策的复杂临床、商业性和以患者为中心的动态。

子宫内膜异位症仍然是一种复杂多样的疾病，存在着许多未被满足的需求，因此人们对治疗方法的发现、製剂的创新以及以患者为中心的护理模式持续保持关注。诊断敏感性的提高和临床医生认识的增强正在重塑临床路径，促进早期疗育和荷尔蒙疗法及非荷尔蒙疗法的更广泛应用。因此，製药公司和医疗保健系统正在重新评估优先事项，以平衡症状性疼痛管理、生育治疗和长期缓解疾病。

对标靶治疗、输送技术创新和不断变化的报销模式如何重塑子宫内膜异位症的临床实践和商业策略进行了深入分析。

子宫内膜异位症治疗领域正经历一场变革，其驱动力包括作用机制特异性的提升、给药技术的创新以及相关人员期望的改变。针对荷尔蒙路径和发炎介质的精准医疗方法日益成熟，加速了人们对广泛荷尔蒙抑制疗法和镇痛药依赖性的重新评估。同时，长效注射剂和改良的口服製剂提高了患者的依从性和耐受性，从而推动了临床诊疗流程和患者体验的改变。

对 2025 年美国关税调整对子宫内膜异位症治疗的供应链、定价策略和临床试验物流的连锁反应影响进行详细检验。

美国在2025年实施的高额关税对子宫内膜异位症治疗生态系统产生了多方面的影响，从采购、生产、定价到临床试验物流，各个环节都受到了连锁反应。依赖进口原料药和成品药的製造商被迫重新审视其供应商关係和库存策略，以缓解不断上涨的成本压力。为此，一些机构正在加快供应商多元化和近岸外包的步伐，以降低关税波动带来的风险，并在不影响产品品质的前提下保护利润率。

将治疗领域、分销管道、给药途径、终端用户环境和作用机制与策略重点和临床差异化联繫起来的综合細項分析。

对关键市场细分进行详细分析，揭示了治疗领域、分销策略、产品类型、给药途径、终端用户环境和作用机制如何塑造市场动态和投资重点。依药物类别划分，相关人员需要管理包括Aromatase抑制剂、促性腺激素释放激素类似物、非类固醇抗发炎药、口服避孕药和黄体素在内的产品组合。值得注意的是，促性腺激素释放激素类似物分为缓释製剂和速效製剂，口服避孕药分为双相、单相和三相给药方案。製剂策略和给药间隔决定了药物在患者依从性、副作用管理和怀孕目标方面的定位。基于分销管道，製造商和支付方需要考虑医院药房、线上药房和零售药房独特的营运和定价因素。医院药局分为私立和公立，零售药局分为连锁店和独立药房，线上模式分为直接面向消费者的平台和平台型市场。每个通道都有其自身的病患入院途径和边界结构，这些都会影响通道配置决策。

透过对美洲、欧洲、中东和非洲以及亚太地区的战略区域洞察，分析细微的监管差异、支付方期望和分销动态，有助于确定上市顺序。

区域趋势对子宫内膜异位症治疗药物的临床应用、监管策略和商业性开发有显着影响。在美洲，集中的临床研究中心、以支付主导的报销机制以及先进的专科药房网络加速了差异化治疗方法的应用，同时也提高了对卫生经济学证据和患者报告结局的需求。因此，在该地区运营的公司必须将临床创新与强有力的支付方参与和真实世界证据策略相结合。在欧洲、中东和非洲，核准週期和报销途径的区域差异使得区域上市顺序和本地证据生成成为必要。公立医院的采购趋势和国家处方药目录流程也会影响药物的可及性和价格谈判。在亚太地区，诊断能力的快速提升、女性健康意识的增强以及私人医疗网络的扩张为品牌药和学名药的发展创造了有利条件。然而，成功取决于符合当地文化的患者支援、具有成本效益的分销模式以及满足各国特定的监管要求。

本书从公司层面提供了实用见解，重点关注研发深度、生产规模、伙伴关係关係以及以患者为中心的商业性能力，这些因素决定了子宫内膜异位症治疗领域的竞争优势。

在子宫内膜异位症治疗领域，各公司的竞争地位取决于研发深度、产品系列广度、生产规模以及在真实临床环境中证明其价值的能力。拥有广泛开发平臺的药物研发公司往往专注于机制特异性的临床差异化和长期疗效研究。同时，专注于特定适应症、新型给药系统以及加速药物上市的合作计画。学名药生产商利用其成熟的生产网络和成本效益高的分销管道，在确保治疗的连续性方面发挥着至关重要的作用，从而保证了药物的可负担性和规模化。合约研发生产机构（CDMO）和受託研究机构（CRO）透过实现在地化生产和高效的临床试验执行，进一步加快了药物上市速度。

为发展和商业领域的领导者提供切实可行的策略建议，以加强证据、实现供应链多元化、优化通路并与支付方的优先事项保持一致。

行业领导者可以采取多项切实可行的措施，在当前的临床和商业环境中保持患者用药可及性并创造长期价值。首先，应优先考虑将临床终点与支付方相关结果和病患报告指标结合的证据策略。在核心试验的同时开展真实世界证据项目，有助于提升报销地位并支持差异化产品标籤。其次，应实现供应链多元化，探索近岸外包和区域製造伙伴关係，以降低关税相关风险并确保供应连续性，尤其对于注射剂和温度敏感製剂。

透过高度透明的调查方法，结合专家访谈、监管和临床资料整合、情境分析和跨领域检验，可以获得可操作的见解。

本执行摘要的调查方法整合了定性研究、严谨的二手资讯分析以及与监管和临床资料储存库的交叉验证，以确保其稳健性和适用性。一手资料包括对临床专家、处方集管理人员和供应链负责人进行的结构化访谈，以了解他们对治疗效果、获取障碍和营运风险的实际观点。二手分析利用同行评审的临床文献、监管核准和安全性摘要、临床试验註册信息、专利和公开的企业披露信息，绘製治疗产品线、按作用机制分類的证据以及产品生命週期事件图谱。

结论强调，临床区分、供应链韧性和真实世界证据的一致性对于实现可持续的影响和可近性至关重要。

总之，目前子宫内膜异位症的治疗现况呈现出临床创新融合、分销模式转变以及支付方监管加强的趋势。治疗方法的差异化越来越依赖将特定机制的疗效与可证实的患者预后和切实可行的治疗模式结合。同时，关税调整和供应链中断等外部压力凸显了商业化计画中营运韧性和区域适应性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 子宫内膜异位症治疗市场：依药物类别划分

  • Aromatase抑制剂
  • GnRH类似物
    • 长效型
    • 短效
  • 非类固醇消炎剂（NSAIDs）
  • 口服避孕药
    • 双相
    • 单相
    • 三相
  • 黄体素

第九章 子宫内膜异位症治疗市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用製剂

第十章 依作用机转分割的子宫内膜异位症治疗药物市场

  • 荷尔蒙疗法
  • 疼痛管理

第十一章 子宫内膜异位症治疗市场：依产品类型划分

  • 品牌商品
  • 学名药

第十二章 子宫内膜异位症治疗市场：依分销管道划分

  • 医院药房
    • 私立医院药房
    • 公立医院药房
  • 网路药房
    • 面向消费者的线上药房
    • 基于平台的线上药房
  • 零售药房
    • 连锁零售药局
    • 独立零售药房

第十三章 子宫内膜异位症治疗市场：依最终使用者划分

  • 诊所
  • 家庭医疗保健
  • 医院

第十四章 子宫内膜异位症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 子宫内膜异位症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 子宫内膜异位症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国子宫内膜异位症治疗市场

第十八章：中国子宫内膜异位症治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Limited
  • Ferring Pharmaceuticals
  • Ferring Pharmaceuticals Inc.
  • Myovant Sciences GmbH
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-2B5802CFEB6F

The Endometriosis Drugs Market was valued at USD 2.89 billion in 2025 and is projected to grow to USD 3.11 billion in 2026, with a CAGR of 7.49%, reaching USD 4.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.89 billion
Estimated Year [2026] USD 3.11 billion
Forecast Year [2032] USD 4.80 billion
CAGR (%) 7.49%

Comprehensive introduction that frames the complex clinical, commercial, and patient-centric dynamics shaping endometriosis therapeutics and strategic decision-making

Endometriosis remains a complex and heterogeneous condition with significant unmet clinical need, driving sustained interest across therapeutic discovery, formulation innovation, and patient-centered care models. Recent advances in diagnostic sensitivity and clinician awareness have reshaped clinical pathways, prompting earlier intervention and broader utilization of both hormonal and non-hormonal strategies. Consequently, drug developers and healthcare systems are recalibrating priorities to balance symptomatic pain management, fertility preservation, and long-term disease modification.

Against this evolving clinical backdrop, the intersection of legacy pharmacotherapies and emerging targeted agents creates strategic complexity for stakeholders. Oral contraceptives, progestins, non-steroidal anti-inflammatory drugs (NSAIDs), aromatase inhibitors, and gonadotropin-releasing hormone (GnRH) analogs collectively underpin current practice, but differential efficacy, tolerability, and delivery formats influence clinician prescribing and patient adherence. As a result, organizations must integrate clinical evidence, patient preference, and payer dynamics to design differentiated value propositions that are both clinically meaningful and commercially viable.

Moreover, shifting distribution channels and the digitalization of patient support programs are changing how therapies reach end users. These dynamics necessitate an integrated view that pairs scientific insights with pragmatic commercial planning to ensure therapies move from development into sustainable use. The purpose of this executive summary is to distill those cross-cutting insights and to orient leaders toward high-impact decisions that preserve therapeutic value while responding to patient and health system needs.

Insightful analysis of how targeted therapies, delivery innovations, and evolving reimbursement models are reshaping clinical practice and commercial strategy in endometriosis

The landscape for endometriosis therapeutics is undergoing transformative shifts driven by advances in mechanism-of-action specificity, delivery innovations, and evolving stakeholder expectations. Precision approaches that target hormonal pathways and inflammatory mediators are maturing, prompting a re-evaluation of long-standing reliance on broad hormonal suppression and analgesics. At the same time, long-acting injectable formulations and optimized oral agents are improving adherence and tolerability profiles, which in turn alters clinical algorithms and patient journeys.

Concurrently, commercialization models are adapting to digital engagement and value-based contracting, which emphasize real-world outcomes and total cost of care. Patient-reported outcomes and decentralized care models increasingly inform reimbursement discussions, forcing manufacturers to demonstrate tangible improvements in quality of life beyond symptom relief. Supply chain resilience and regulatory harmonization efforts are also reshaping launch strategies, as companies seek to minimize time-to-patient while ensuring consistent availability across hospital pharmacies, retail outlets, and online platforms.

Taken together, these shifts create both opportunities and challenges: deeper differentiation through targeted therapies and delivery formats, paired with the need for more sophisticated evidence generation and multi-channel commercialization plans. Leaders who integrate clinical differentiation with rigorous engagement of payers, clinicians, and patients will capture the greatest long-term value in this rapidly evolving market.

In-depth examination of the cascading effects of 2025 United States tariff adjustments on supply chains, pricing strategies, and clinical trial logistics across endometriosis therapeutics

The introduction of elevated United States tariffs in 2025 has exerted a multi-dimensional influence on the endometriosis drug ecosystem, with effects that cascade through sourcing, manufacturing, pricing, and clinical trial logistics. Manufacturers that rely on imported active pharmaceutical ingredients or finished formulations have had to reassess supplier relationships and inventory strategies to mitigate incremental cost pressure. In response, several organizations accelerated supplier diversification and nearshoring initiatives to reduce exposure to tariff volatility and to protect margins without degrading product quality.

At the same time, procurement teams within hospitals and clinic networks adjusted purchasing cadence and inventory buffers to absorb episodic cost increases while preserving patient access. These operational shifts have implications for distribution channels, particularly for hospital pharmacies that manage large institutional formularies and for online pharmacies that operate on narrow margin structures. Moreover, the tariff environment intensified dialogue between manufacturers and payers about allowable price adjustments and risk-sharing mechanisms, pushing some stakeholders toward outcome-based contracting to preserve affordability for patients.

Regulatory and clinical operations were not immune: tariffs compelled sponsors to re-evaluate cross-border clinical supply chains and shipment strategies for investigational products, influencing how trials were timed and where localized manufacturing could provide contingency. In aggregate, the 2025 tariff changes reinforced the strategic importance of supply chain agility, localized production capabilities, and collaborative commercial models that share risk and preserve continuity of care.

Comprehensive segmentation insights that link therapeutic class, distribution channels, administration routes, end-user settings, and mechanisms of action to strategic priorities and clinical differentiation

A granular view across key market segmentation highlights how therapeutic class, distribution strategy, product type, administration route, end-user environment, and mechanism of action each shape competitive dynamics and investment priorities. Based on drug class, stakeholders must navigate portfolios that include aromatase inhibitors, GnRH analogs, NSAIDs, oral contraceptives, and progestins, noting that GnRH analogs are differentiated into long-acting and short-acting formulations while oral contraceptives span biphasic, monophasic, and triphasic regimens; formulation strategy and dosing cadence determine patient adherence, side effect management, and positioning relative to fertility goals. Based on distribution channel, manufacturers and payers must account for the distinct operational and pricing considerations of hospital pharmacies, online pharmacies, and retail pharmacies, with the former divided into private and public hospital pharmacies, the latter including chain and independent retail pharmacies, and online models split between direct-to-consumer platforms and platform-based marketplaces; each channel presents unique patient access pathways and margin structures that influence channel mix decisions.

Based on product type, differentiation between branded and generic offerings influences lifecycle strategies, promotional tactics, and pricing discipline. Based on route of administration, therapeutic impact and patient preference diverge across injectable, oral, and topical options, with injectables often offering adherence advantages for long-acting GnRH analogs and orals providing convenience for contraceptive and NSAID regimens. Based on end user, clinical delivery contexts differ among clinics, home healthcare settings, and hospitals, and each environment requires tailored support programs, training protocols, and supply chain adaptations to ensure appropriate administration and monitoring. Finally, based on mechanism of action, the market is organized around hormonal therapy and pain management approaches, a distinction that drives clinical trial endpoints, labeling strategies, and reimbursement narratives. Integrating these segmentation perspectives reveals where clinical need aligns with commercial opportunity, and where targeted evidence generation can unlock access and differentiate products in crowded categories.

Strategic regional insight that maps regulatory nuance, payer expectations, and distribution dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform launch sequencing

Regional dynamics exert substantial influence over clinical adoption, regulatory strategy, and commercial execution for endometriosis therapeutics. In the Americas, concentrated centers of clinical research, payer-driven reimbursement frameworks, and sophisticated specialty pharmacy networks accelerate uptake of differentiated therapies while heightening demands for health economic evidence and patient-reported outcomes; consequently, companies operating in this region must pair clinical innovation with robust payer engagement and real-world evidence strategies. In Europe, Middle East & Africa, the regulatory landscape is heterogeneous, with varying approval timelines and reimbursement pathways that require nuanced regional launch sequencing and local evidence generation; public hospital procurement dynamics and national formulary processes further shape access and pricing negotiations. In Asia-Pacific, rapid enhancements in diagnostic capability, growing awareness of women's health, and expanding private healthcare networks create fertile ground for both branded and generic entrants, but success hinges on culturally appropriate patient support, cost-effective distribution models, and navigation of country-specific regulatory expectations.

Across all regions, cross-border differences in supply chain resilience, tariff exposure, and clinical practice guidelines necessitate differentiated commercialization playbooks. Consequently, organizations should prioritize region-specific evidence plans, targeted stakeholder engagement, and scalable distribution partnerships to translate therapeutic advances into sustained patient access and commercial performance.

Actionable company-level insights focusing on R&D depth, manufacturing scale, partnerships, and patient-centric commercial capabilities that determine competitive success in endometriosis therapeutics

Competitive positioning among companies in the endometriosis therapeutics space is shaped by R&D depth, portfolio breadth, manufacturing scale, and the ability to demonstrate real-world value. Innovator pharmaceutical companies with deep development pipelines tend to emphasize mechanism-specific clinical differentiation and long-term outcome studies, while specialty biotechs and clinical-stage developers focus on niche indications, novel delivery systems, and partnerships to accelerate access. Generic manufacturers play a critical role in ensuring affordability and scale, often leveraging established manufacturing networks and cost-efficient distribution channels to maintain continuity of care. Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) further influence speed to market by enabling localized production and efficient trial execution.

Strategically, companies that integrate clinical excellence with patient support programs and multi-channel distribution gain a competitive edge. Firms that invest in long-acting formulations or in delivery platforms that reduce clinic burden can capture durable adherence benefits, while those that prioritize interoperability with digital health tools can strengthen patient engagement and post-market evidence collection. Partnerships between large pharmaceutical firms and smaller innovators, especially when coupled with flexible licensing and co-commercialization agreements, are common vehicles to scale novel therapies rapidly across multiple geographies. Ultimately, the most successful organizations balance scientific differentiation with pragmatic commercial and operational capabilities to translate clinical promise into sustained patient impact.

Actionable strategic recommendations for developers and commercial leaders to strengthen evidence, diversify supply chains, optimize distribution channels, and align with payer priorities

Industry leaders can adopt several pragmatic actions to navigate the current clinical and commercial environment while preserving patient access and long-term value creation. First, prioritize evidence strategies that align clinical endpoints with payer-relevant outcomes and patient-reported measures; building real-world evidence programs alongside pivotal trials strengthens reimbursement positioning and supports differentiated labeling. Second, diversify supply chains and consider nearshoring or regional manufacturing partnerships to mitigate tariff-related exposure and to ensure continuity of supply, particularly for injectable and temperature-sensitive formulations.

Third, design distribution strategies that reflect channel economics and patient behavior: integrate hospital pharmacy engagement for inpatient and specialty use, optimize retail pharmacy relationships for chronic oral therapies, and leverage direct-to-consumer and platform-based online pharmacy models to enhance convenience and adherence. Fourth, invest in long-acting delivery and digital patient support tools to improve adherence, reduce clinic visits, and generate longitudinal outcomes data that payers value. Fifth, explore collaborative contracting models with payers, such as outcomes-based agreements, to share risk and demonstrate commitment to affordability. Finally, cultivate partnerships across the ecosystem-academic centers, specialty clinics, and patient advocacy organizations-to co-develop education initiatives and accelerate adoption while ensuring that patient voices inform product design and post-market support.

Transparent research methodology combining expert interviews, regulatory and clinical data synthesis, scenario analysis, and cross-segmentation validation to ensure actionable insights

The research methodology underpinning this executive summary integrates primary qualitative engagement, rigorous secondary source analysis, and cross-validation with regulatory and clinical data repositories to ensure robustness and applicability. Primary inputs include structured interviews with clinical experts, formulary managers, and supply chain leaders to capture frontline perspectives on therapeutic performance, access barriers, and operational risks. Secondary analysis draws on peer-reviewed clinical literature, regulatory approvals and safety summaries, clinical trial registries, patents, and publicly available corporate disclosures to map therapeutic pipelines, mechanism-specific evidence, and product lifecycle events.

Analytical techniques include cross-segmentation synthesis to align therapeutic classes with distribution and administration dynamics, scenario analysis to evaluate tariff and supply chain disruptions, and stakeholder mapping to prioritize payer and provider engagement. Findings were subjected to expert validation rounds to refine interpretations and to ensure that strategic recommendations are practical and aligned with current regulatory and clinical realities. Care was taken to avoid reliance on proprietary market-sizing models, instead favoring transparent, evidence-based reasoning that supports decision-making for product development and commercialization.

Concluding synthesis that underscores the necessity of aligning clinical differentiation, supply chain resilience, and real-world evidence to achieve sustained impact and access

In conclusion, the endometriosis therapeutics landscape is characterized by a convergence of clinical innovation, shifting distribution paradigms, and heightened payer scrutiny. Therapeutic differentiation increasingly depends on aligning mechanism-specific benefits with demonstrable patient outcomes and practical delivery models. At the same time, external pressures such as tariff changes and supply chain disruption underscore the importance of operational resilience and regional adaptability in commercialization planning.

Organizations that succeed will combine rigorous evidence generation with agile manufacturing and a multi-channel distribution strategy that respects local regulatory and payer environments. By centering patient experience and incorporating real-world data into both clinical and commercial plans, stakeholders can accelerate access to effective therapies while building sustainable business models. The collective imperative is clear: integrate clinical innovation with pragmatic execution to deliver meaningful improvements in patient care and to realize long-term commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometriosis Drugs Market, by Drug Class

  • 8.1. Aromatase Inhibitors
  • 8.2. GnRH Analogs
    • 8.2.1. Long-Acting
    • 8.2.2. Short-Acting
  • 8.3. NSAIDs
  • 8.4. Oral Contraceptives
    • 8.4.1. Biphasic
    • 8.4.2. Monophasic
    • 8.4.3. Triphasic
  • 8.5. Progestins

9. Endometriosis Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Endometriosis Drugs Market, by Mechanism Of Action

  • 10.1. Hormonal Therapy
  • 10.2. Pain Management

11. Endometriosis Drugs Market, by Product Type

  • 11.1. Branded
  • 11.2. Generic

12. Endometriosis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
    • 12.1.1. Private Hospital Pharmacies
    • 12.1.2. Public Hospital Pharmacies
  • 12.2. Online Pharmacies
    • 12.2.1. Direct-To-Consumer Online Pharmacies
    • 12.2.2. Platform-Based Online Pharmacies
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Retail Pharmacies
    • 12.3.2. Independent Retail Pharmacies

13. Endometriosis Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals

14. Endometriosis Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Endometriosis Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Endometriosis Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Endometriosis Drugs Market

18. China Endometriosis Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. Dr. Reddy's Laboratories Limited
  • 19.8. Ferring Pharmaceuticals
  • 19.9. Ferring Pharmaceuticals Inc.
  • 19.10. Myovant Sciences GmbH
  • 19.11. Pfizer Inc.
  • 19.12. Sandoz International GmbH
  • 19.13. Sun Pharmaceutical Industries Limited
  • 19.14. Takeda Pharmaceutical Company Limited
  • 19.15. Teva Pharmaceutical Industries Ltd.
  • 19.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DIRECT-TO-CONSUMER ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DIRECT-TO-CONSUMER ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DIRECT-TO-CONSUMER ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PLATFORM-BASED ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PLATFORM-BASED ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PLATFORM-BASED ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CHAIN RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY GNRH ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)